ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIRO..CY..TR................................................JBDM Ver 0.1.67 (18 Oct 2017) - 2999001/03351246CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120190918W173deBibliographieenBibliographyfrBibliographieEP18155644.0200202182018020720190118enenen010407220010219GB012495720011017GB2019091820193820180725201830201905222019212019041020190918201938A61K 31/436 20060101AFI20180601BHEP A61P 35/00 20060101ALI20180601BHEP A61P 35/04 20060101ALI20180601BHEP deRAPAMYCIN-DERIVAT ZUR BEHANDLUNG EINES SOLIDEN TUMORS, DER MIT DEREGULIERTER ANGIOGENESE ASSOZIIERT ISTenRAPAMYCIN DERIVATIVE FOR THE TREATMENT OF A SOLID TUMOR ASSOCIATED WITH DEREGULATED ANGIOGENESISfrDÉRIVÉ DE RAPAMYCINE POUR LE TRAITEMENT D'UNE TUMEUR SOLIDE ASSOCIÉE À UNE ANGIOGENÈSE DÉRÉGULÉEWO-A1-01/51049WO-A1-94/09010WO-A1-97/47317US-A- 5 206 018GUBA M ET AL: "RAPAMYCIN INHIBIERT DAS TUMORWACHTSUM UND DIE TUMORMETASTASIERUNG UEBER ANTIANGIOGENESE//RAPAMYCIN INHIBITS TUMOR GROWTH AND METASTASIS BY ANTIANGIOGENESIS", CHIRURGISCHES FORUM FUER EXPERIMENTELLE UND KLINISCHE FORSCHUNG, BERLIN, DE, 1 January 2001 (2001-01-01), pages 37-39, XP001088707, ISSN: 0303-6227SHAH SHIMUL A ET AL: "FRAP-p70s6K Signaling Is Required for Pancreatic Cancer Cell Proliferation", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 97, no. 2, 2 November 2000 (2000-11-02), pages 123-130, XP029590080, ISSN: 0022-4804, DOI: 10.1006/JSRE.2001.6145HIDALGO M ET AL: "THE RAPAMYCIN-SENSITIVE SIGNAL TRANSDUCTION PATHWAY AS A TARGET FOR CANCER THERAPY", ONCOGENE, NATURE PUBLISHING GROUP UK, LONDON, vol. 19, no. 56, December 2000 (2000-12), pages 6680-6686, XP009002368, ISSN: 0950-9232, DOI: 10.1038/SJ.ONC.1204091SEUFFERLEIN T ET AL: "Constitutive activation of p70s6k in human pancreatic cancer cell lines bearing activating Ki-ras mutations", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, vol. 114, 15 April 1998 (1998-04-15), page A496, XP027466913, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(98)82012-X [retrieved on 1998-04-15]SEUFFERLEIN THOMAS ET AL: "Rapamycin inhibits constitutive p70-s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells", CANCER RESEARCH, AACR - AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 56, no. 17, 1996, pages 3895-3897, XP002766076, ISSN: 0008-5472HIDALGO M ET AL: "A phase I and pharmacological study of CCI-779, a rapamycin ester cell cycle inhibitor. ADIS TITLE: CCI 779: therapeutic use Solid tumours Phase I trial", ANNALS OF ONCOL, KLUWER, DORDRECHT, NL, vol. 11, no. Suppl. 4, 2000, page 133, XP009193116, ISSN: 0923-7534HIDALGO M ET AL: "CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study. ADIS TITLE: CCI 779: therapeutic use Solid tumours Phase I trial", PROGRAM/PROCEEDINGS - AMERICAN SOCIETY OF CLINICAL ONCOLOGY, THE SOCIETY, US, vol. 19, 2000, page 187, XP009193117, ISSN: 1081-0641TSUCHIYA N ET AL: "EFFECTS OF FADROZOLE AND LEUPRORELIN ACETATE ON AROMATASE ACTIVITY AND CELL PROLIFERATION IN A HUMAN BREAST CANCER CELL LINE (SK-BR-3)", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, CHURCHILL LIVINGSTONE JAPAN, TOKYO, GB, vol. 5, 1 January 2000 (2000-01-01), pages 183-187, XP001069645, ISSN: 1341-9625BUZDAR A ET AL: "Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 7, no. 9, 1 September 2001 (2001-09-01), pages 2620-2635, XP002784456, ISSN: 1078-0432CLEMETT DELYTH ET AL: "Exemestane: A review of its use in postmenopausal women with advanced breast cancer", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 59, no. 6, 1 June 2000 (2000-06-01), pages 1279-1296, XP002784405, ISSN: 0012-6667GOSS P E ET AL: "Aromatase inhibitors in the treatment and prevention of breast cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 19, no. 3, 1 February 2001 (2001-02-01), pages 881-894, XP003022842, ISSN: 0732-183XYU K ET AL: "MTOR, A NOVEL TARGET IN BREAST CANCER: THE EFFECT OF CCI-779, AN MTOR INHIBITOR, IN PRECLINICAL MODELS OF BREAST CANCER", ENDOCRINE - RELATED CANCER, BIOSCIENTIFICA LTD, GB, vol. 8, no. 3, 1 September 2001 (2001-09-01), pages 249-258, XP001079023, ISSN: 1351-0088, DOI: 10.1677/ERC.0.008024916186041.631439952016082614164259.527836862014041002719864.7136362720020218Lane, HeidiKaltbrunnenweg 84106 TherwillCHO`Reilly, TerenceDrahtzugstrasse 514057 BaselCHWood, Jeanette MarjorieIn den Kleematten 184105 Biel-BenkenCHNovartis Pharma AG100966220P073583EP:CJMLichtstrasse 354056 BaselCHNovartis International Pharmaceutical AG101823421P073583EP:CJMLichtstrasse 354056 BaselCHCarpmaels & Ransford LLP101299776One Southampton RowLondon WC1B 5HAGB01201905231STADA Arzneimittel AG100705187Stadastrasse 2-1861118 Bad VilbelDEHamm&Wittkopp Patentanwälte PartmbBet al101576032Jungfernstieg 3820354 HamburgDE02201907011BIOGARAN10183166715 Boulevard Charles de Gaulle92707 COLOMBESFRCasalonga101339021Casalonga & Partners Bayerstraße 71/7380335 MünchenDE03201907031Ethypharm101578848194 Bureaux de la Colline92213 Saint-CloudFRLLRet al10170361611, boulevard de Sébastopol75001 ParisFR04201907310Accord Healthcare Ltd101261282Sage House 319 Pinner RoadNorth Harrow Middlesex HA1 4HFGBPlougmann Vingtoft a/s101215840Strandvejen 702900 HellerupDKATBECHCYDEDKESFIFRGBGRIEITLILUMCNLPTSETRLT20180207LV20180207RO20180207SI20180207